Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if there is an excess risk of acute kidney injury (AKI) with Serotonin-norepinephrine reuptake inhibitors (SNRIs) as compared to Selective serotonin reuptake inhibitors (SSRIs), two classes of medication used for the treatment of depression.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
• Collaborators: Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness Network, Canada
• Treatments: Citalopram; Desvenlafaxine Succinate; Dexetimide; Duloxetine Hydrochloride; Fluoxetine; Fluvoxamine; Norepinephrine; Paroxetine; Serotonin; Sertraline; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• A first prescription of an antidepressant of the SNRI or SSRI class of any dose between January 1, 1997 and March 31, 2010.

Exclusion Criteria:

• They were <12 years old at the time of cohort entry.

• They had less than 1 year of information in the database prior to the date of cohort entry.

• They had a prescription of an SNRI or SSRI in the year before the date of cohort entry.

• They had a prescription for both an SNRI and an SSRI on the day of cohort entry.

• They had a history of chronic kidney disease (including kidney transplantation and dialysis) or AKI in the year preceding cohort entry.

• The subject was previously included in the cohort.